Skip to Content
MilliporeSigma
All Photos(1)

Documents

EHU052971

Sigma-Aldrich

MISSION® esiRNA

targeting human TRIM37

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CATCTTAGCCCCCAAAATGATGATGCTCTGGAGACACGAGCTAAGAAGTCTGCATGCTCTGACATGCTTCTCGAAGGTGGTCCTACTACAGCTTCTGTAAGAGAGGCCAAAGAGGATGAAGAAGATGAGGAGAAGATTCAGAATGAAGATTATCATCACGAGCTTTCAGATGGAGATCTGGATCTGGATCTTGTTTATGAGGATGAAGTAAATCAGCTCGATGGCAGCAGTTCCTCTGCTAGTTCCACAGCAACAAGTAATACAGAAGAAAATGATATTGATGAAGAAACTATGTCTGGAGAAAATGATGTGGAATATAACAACATGGAATTAGAAGAGGGAGAACTCATGGAAGATGCAGCTGCTGCAGGACCCGCAGGTAGTAGCCATGGTTATGTGGGTTCCAGTAGTAGAATATCAAGAAGAACACATTTATGCTCCGCTGCTACC

Ensembl | human accession no.

ENSG00000108395

NCBI accession no.

NM_015294

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... TRIM37(4591) , TRIM37(4591)

Related Categories

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Guosheng Tan et al.
International journal of clinical oncology, 26(3), 532-542 (2021-01-03)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer in the worldwide. Sorafenib is approved for first-line therapy against advanced HCC, but chemo-resistance is still a leading cause of tumor relapse and treatment failure in HCC. Thus, there is
Fernando R Balestra et al.
eLife, 10 (2021-01-26)
TRIM37 is an E3 ubiquitin ligase mutated in Mulibrey nanism, a disease with impaired organ growth and increased tumor formation. TRIM37 depletion from tissue culture cells results in supernumerary foci bearing the centriolar protein Centrin. Here, we characterize these centriolar

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service